Nathaniel B. Phillips-Sylvain

FDA investigator · also recorded as Re Nathaniel Phillips-Sylvain, I. Nataniel Phillips-Sylvain

Appears on 6 documents from 2020 to 2022, mostly at sites in Washington. Most often cites production record review (21 CFR 211.192).

6
Documents on file
2.4
Observations per 483
2020
First seen
2022
Most recent

What they cite most

From 28 observations

Activity by year

2020: 2, 2021: 2, 2022: 2

Where

Washington 3 · Arizona 1 · California 1 · Oregon 1

Is Nathaniel B. Phillips-Sylvain coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

6 documents, newest first
FirmOpen
483 Lonza Bend Inc.Aug 5, 2022 · Bend, Oregon
483 Omya Inc.May 27, 2022 · Superior, Arizona
483 AGC Biologics, Inc.Mar 19, 2021 · Bothell, Washington
483 First Pharma Associates LLC dba Riverpoint PharmacyMar 3, 2021 · Spokane, Washington
483 Form 483 · FEI 3014577316Oct 5, 2020 · Tukwila, Washington
483 La Vita Compounding Pharmacy, LLCMar 11, 2020 · San Diego, California

About this profile

What does Nathaniel B. Phillips-Sylvain inspect?

Nathaniel B. Phillips-Sylvain appears on 6 documents on file covering 6 sites, mostly in Washington.

What do they cite most often?

21 CFR 211.192 (production record review), followed by FDCA 501(a)(2)(A) and 21 CFR 211.100.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Nathaniel B. Phillips-Sylvain is dated Aug 5, 2022.